NCCN Guidelines® Insights: Esophageal and Esophagogastric Junction Cancers, Version 4.2026
Journal of the National Comprehensive Cancer Network · 2026-09 · 24 (9)
DOI: 10.6004/jnccn.2026.0043 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-09. Verfasst von Jaffer A Ajani und 42 weiteren Autor:innen. Beteiligte Einrichtung: 1The University of Texas MD Anderson Cancer Center. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophagogastric Junction, Adenocarcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben.
Abstract (Originalsprache)
Esophageal cancer is the seventh leading cause of cancer-related deaths worldwide. Esophageal cancers are histologically classified as squamous cell carcinoma (ESCC) or adenocarcinoma (EAC), which differ in their etiology, pathology, tumor location, therapeutics, and prognosis. In patients with locally advanced or metastatic disease, systemic therapy can provide palliation, improve survival, and/or enhance quality of life. The implementation of biomarker testing and immunotherapy has had a significant impact on clinical practice and patient care. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers highlights current recommendations for advanced ESCC, including the evolving landscape of first-line immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1The University of Texas MD Anderson Cancer Center.
- 2Duke Cancer Institute.
- 3Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
- 4Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
- 5UCSF Helen Diller Family Comprehensive Cancer Center.
- 6Dana-Farber/Brigham and Women's Cancer Center.
Zitieren
APA
Ajani, J. A., D'Amico, T. A., Bentrem, D. J., Chakrabarti, S., Corvera, C. U., Das, P., Enzinger, P. C., Enzler, T., Gerdes, H., Gibson, M. K., Grierson, P., Gupta, G., Hofstetter, W. L., Ilson, D. H., Jalal, S., Jin, N., Kim, S., Klempner, S., Kukar, M., …, & Stein, M. (2026). NCCN Guidelines® Insights: Esophageal and Esophagogastric Junction Cancers, Version 4.2026. Journal of the National Comprehensive Cancer Network, 24(9). https://doi.org/10.6004/jnccn.2026.0043
Vancouver
Ajani JA, D'Amico TA, Bentrem DJ, Chakrabarti S, Corvera CU, Das P, et al. NCCN Guidelines® Insights: Esophageal and Esophagogastric Junction Cancers, Version 4.2026. Journal of the National Comprehensive Cancer Network. 2026;24(9). doi:10.6004/jnccn.2026.0043
BibTeX
@article{Ajani2026,
author = {Ajani, Jaffer A and D'Amico, Thomas A and Bentrem, David J and Chakrabarti, Sakti and Corvera, Carlos U and Das, Prajnan and Enzinger, Peter C and Enzler, Thomas and Gerdes, Hans and Gibson, Michael K and Grierson, Patrick and Gupta, Garima and Hofstetter, Wayne L and Ilson, David H and Jalal, Shadia and Jin, Ning and Kim, Sunnie and Klempner, Samuel and Kukar, Moshim and Lacy, Jill and Lam, Vincent and Lee, Byrne and Licciardi, Frank and Lloyd, Shane and Ly, Quan P and Matsukuma, Karen and Merkow, Ryan P and Miller, Aaron M and Mulcahy, Mary F and Perry, Kyle A and Pimiento, Jose M and Reddi, Deepti M and Reznik, Scott and Roses, Robert E and Sedarat, Alireza and Strong, Vivian E and Su, Stacey and Uboha, Nataliya and Willett, Christopher G and Yoon, Harry H and McMillian, Nicole R and Sansone, Nicholas and Stein, MaryElizabeth},
title = {NCCN Guidelines® Insights: Esophageal and Esophagogastric Junction Cancers, Version 4.2026},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {9},
doi = {10.6004/jnccn.2026.0043}
}
EUVIMED